DNAI 6.99 Earnings and upcoming catalyst Phase II update from March.03 and technical chart article pasted .
ProNAi Reports 2015 Year-End Financial and Operational Results
ProNAi Therapeutics Inc. March 3, 2016 7:00 AM
VANCOUVER , March 3, 2016 /CNW/- ProNAi Therapeutics, Inc. (DNAI), a clinical-stage oncology company advancing novel therapeutics for patients with cancer and hematological diseases, today reported its financial and operational results for the year ended December 31, 2015 .
"During 2015, we continued to transform ProNAi into a world-class oncology drug development company, securing both the talent and capital required to pursue our vision of developing and commercializing a pipeline of promising clinical-stage oncology assets with the potential to provide meaningful therapeutic outcomes to patients with cancer," said Dr. Nick Glover , President and CEO of ProNAi Therapeutics. "Concurrent with building our company, we continued to advance our lead asset PNT2258, operationalizing two Phase 2 trials in 2015, Wolverine and Brighton , that are at the forefront of a concerted registration-oriented clinical development program planned for the drug. In addition to PNT2258, during 2015 we began evaluating novel product candidates available for licensing or acquisition, with the goal of maximizing our clinical development capabilities and leveraging the full potential of our team by advancing a broad and diversified pipeline of assets."
"We anticipate reporting initial interim data from the Wolverine trial in third-line DLBCL in the second quarter of 2016. This trial has been designed to identify and characterize patient populations who respond to PNT2258 on the basis of their genetics and disease characteristics and will be essential to determining potential paths to registration for the drug," added Dr. Glover. "We recently started enrolling the Brighton trial in Richter's transformation and expect to report interim data from this trial before the end of 2016. We are also designing a number of additional Phase 2 trials that could support the registration and commercialization strategies for PNT2258. Two planned trials, Cypress and Granite, will evaluate PNT2258 in combination with standard-of-care treatment regimens for the treatment of second-line DLBCL in the "transplant eligible" and "transplant ineligible" patient populations respectively. We are also designing trials evaluating PNT2258's potential in DLBCL in combination with a targeted anti-cancer drug, and in other hematological malignancies as well. Although we maintain a strong balance sheet, we are carefully considering the timing of these additional trials with a view to maximizing PNT2258's potential while deploying our capital prudently."
2015 Operational Highlights: •Operationalized the Wolverine Phase 2 trial evaluating single-agent PNT2258 in third-line relapsed or refractory DLBCL, opening more than 20 clinical sites during 2015 that are now actively recruiting patients. •Initiated the Brighton Phase 2 trial evaluating single-agent PNT2258 in Richter's transformed CLL. •Completed a successful IPO in July 2015 , raising more than $158 million in gross proceeds. ProNAi shares began trading on the NASDAQ Global Market on July 16, 2015 under the symbol "DNAI." •Strengthened the ProNAi management team, appointing six additional experienced senior executives including Dr. Barbara Klencke , M.D., as Chief Development Officer. Dr. Klencke is an accomplished oncology drug developer with a demonstrable track record of success, having made substantial contributions to the development and approval of several important oncology products including Kyprolis, Kadcyla, Avastin and Tarceva. •Expanded the company from approximately 25 employees to more than 50 employees and opened our corporate headquarters in Vancouver, Canada . •ProNAi (DNAI) was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI)
2015 Financial Results (all amounts reported in U.S. currency) Total operating expenses for the year ended December 31, 2015 were $35.8 million compared to $22.6 million for the year ended December 31, 2014 . Total operating expenses include non-cash stock based compensation of $3.2 million and $0.3 million for the years ended December 31, 2015 and 2014, respectively.
Research and development expenses increased to $26.4 million for the year ended December 31, 2015 from $19.1 million for the year ended December 31, 2014 . These increases were primarily due to expenses related to the continuation of our PNT2258 clinical trials, the manufacture of PNT2258 and an increase in personnel-related costs. Expenses for the year ended December 31, 2014 include a one-time $11.0 million milestone payment that was made to Novosom AG during the second quarter of 2014.
General and administrative expenses increased to $9.5 million for the year ended December 31, 2015 from $3.5 million for the year ended December 31, 2014 . These increases were primarily due to increased personnel-related costs and professional fees incurred in support of activities as a public company and corporate growth.
For the year ended December 31, 2015 , ProNAi incurred a net loss of $53.3 million compared to a net loss of $23.9 million for the year ended December 31 , 2014. The net loss includes a non-cash charge related to the change in fair value of preferred stock warrants of $17.4 million and $1.4 million for the years ended December 31, 2015 and 2014, respectively.
At December 31, 2015 , ProNAi had $150.2 million in cash and cash equivalents compared to $39.2 million in cash, cash equivalents and short-term investments at December 31, 2014 .
At December 31, 2015 , there were approximately 30,058,105 shares of common stock issued and outstanding and 3,522,813 options issued and outstanding.
Article pasted. By Roberto Pedone | 03/04/16 - 07:14 AM EST
ProNAi Therapeutics
A clinical-stage oncology player that's starting to spike within range of triggering a big breakout trade is ProNAi Therapeutics (DNAI) , which develops and commercializes a class of therapeutics based on its DNA interference technology platform for patients with cancer and hematological diseases. This stock has been annihilated by the bears over the last six months, with shares dropping sharply lower by 79.5%.
If you take a glance at the chart for ProNAi Therapeutics, you'll notice that this stock recently formed a double bottom chart pattern, after shares found some buying interest at $5.85 to $5.70 a share. Following that potential bottom, shares of ProNAi Therapeutics have now started to spike sharply higher, and it's quickly trending within range of triggering a big breakout trade above some near-term overhead resistance levels.
Traders should now look for long-biased trade in ProNAi Therapeutics if it manages to break out above its 20-day moving average of $6.57 a share and then above more key resistance levels at $6.62 to around $7 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 143,485 shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.46 to $8.60, or even $9 to its 50-day moving average of $9.53 a share.
Traders can look to buy ProNAi Therapeutics off weakness to anticipate that breakout and simply use a stop that sits right around its new 52-week low of $5.70 a share. One could also buy this stock off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point. (end of article)
I have been adding the last two weeks . Avg cost is 6.59
Market Data 
Markets 
AI
